Bavarian Nordic (OTCPK:BVNRY) has received FDA approval for its vaccine Vimkunya for the prevention of chikungunya. The virus-like particle, or VLP, vaccine is approved for people aged 12 and older.

MENTOR's Chief Policy and Advocacy Officer Abbie Evans, led a pre-Summit half-day advocacy training on Jan. 28, immediately ...

First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger travelers.On track for commercial launch in the U.S. in the ...

First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention ...

Monocle is in Munich with the latest on the “terror attack” as the Bavarian capital kicks off its high-stakes security ...

A driver drove a car into a labor union demonstration in central Munich on Thursday, injuring 30 people including children, ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 59 tables and 54 figures, this 141-page report ?Asia Pacific Preventive Vaccines Market 2022-2032 by Vaccine Type, Disease, ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 62 tables and 55 figures, this 142-page report ?Europe Preventive Vaccines Market 2022-2032 by Vaccine Type, Disease, ...

Universal Orlando Resort has announced that Epic Universe — set to open May 22 — will feature more than 30 dining options ...

The European Commission (EC) has already approved Valneva’s chikungunya vaccine Ixchiq for use in individuals aged 18 years ...